Envestnet Asset Management Inc. lowered its holdings in shares of C.R. Bard, Inc. (NYSE:BCR) by 13.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,795 shares of the medical instruments supplier’s stock after selling 581 shares during the period. Envestnet Asset Management Inc.’s holdings in C.R. Bard were worth $1,218,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in BCR. Monroe Bank & Trust MI raised its position in shares of C.R. Bard by 65.6% in the third quarter. Monroe Bank & Trust MI now owns 447 shares of the medical instruments supplier’s stock valued at $100,000 after buying an additional 177 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in shares of C.R. Bard by 70.4% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock valued at $145,000 after buying an additional 190 shares during the last quarter. Parallel Advisors LLC raised its position in shares of C.R. Bard by 2.8% in the second quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock valued at $164,000 after buying an additional 14 shares during the last quarter. Captrust Financial Advisors acquired a new position in shares of C.R. Bard in the second quarter valued at approximately $192,000. Finally, Choate Investment Advisors acquired a new position in shares of C.R. Bard in the second quarter valued at approximately $201,000. Institutional investors own 79.11% of the company’s stock.

C.R. Bard, Inc. (NYSE:BCR) opened at $333.81 on Tuesday. C.R. Bard, Inc. has a 52-week low of $218.72 and a 52-week high of $337.73. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72. The company has a market cap of $24,382.50, a P/E ratio of 28.89, a P/E/G ratio of 2.56 and a beta of 0.52.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, topping the consensus estimate of $2.96 by $0.06. C.R. Bard had a net margin of 14.75% and a return on equity of 48.28%. The firm had revenue of $989.80 million during the quarter, compared to analyst estimates of $990.64 million. During the same quarter in the prior year, the business posted $2.64 earnings per share. C.R. Bard’s revenue for the quarter was up 5.1% compared to the same quarter last year. equities research analysts expect that C.R. Bard, Inc. will post 11.89 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be given a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a yield of 0.31%. The ex-dividend date is Thursday, December 7th. C.R. Bard’s dividend payout ratio (DPR) is 13.70%.

In other C.R. Bard news, insider Timothy P. Collins sold 8,388 shares of the business’s stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $322.00, for a total transaction of $2,700,936.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Sharon M. Luboff sold 30,252 shares of the business’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $320.00, for a total transaction of $9,680,640.00. The disclosure for this sale can be found here. Insiders have sold 210,032 shares of company stock valued at $68,777,261 in the last ninety days. 0.80% of the stock is currently owned by company insiders.

A number of equities analysts have recently weighed in on BCR shares. ValuEngine lowered shares of C.R. Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Barclays boosted their price objective on shares of C.R. Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research report on Monday, November 6th. Jefferies Group reissued a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a research report on Thursday, September 14th. Cowen reissued a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a research report on Friday, November 3rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of C.R. Bard in a research report on Thursday, October 26th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a strong buy rating to the company. C.R. Bard has an average rating of “Hold” and an average price target of $303.50.

TRADEMARK VIOLATION NOTICE: This article was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.watchlistnews.com/envestnet-asset-management-inc-cuts-holdings-in-c-r-bard-inc-bcr/1772765.html.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard and related companies with MarketBeat.com's FREE daily email newsletter.